MedTrace Logo

A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer

NCT04294160 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 122

Last updated 2025-12-24

No results posted yet for this study

Summary

A phase Ib, open-label platform study of select drug combinations chosen in order to characterize safety and tolerability of each treatment arm tested and to identify recommended doses and regimens for future studies.

Conditions

  • BRAF V600 Colorectal Cancer

Interventions

DRUG

Dabrafenib

Capsule for oral use

DRUG

LTT462

Capsule for oral use

DRUG

Trametinib

Tablet for oral use

DRUG

LXH254

Tablet for oral use

DRUG

TNO155

Capsule for oral use

BIOLOGICAL

Spartalizumab

Liquid in vial (Concentrate for solution for infusion) for intravenous use

BIOLOGICAL

Tislelizumab

Liquid in vial (Concentrate for solution for infusion) for intravenous use

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-22
Primary Completion
2024-09-25
Completion
2024-09-25
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Belgium
  • Canada
  • Germany
  • Israel
  • Netherlands
  • Singapore
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04294160 on ClinicalTrials.gov